Catherine Chenailler

Dr. Catherine Chenailler

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Gerontology
Verified
Journal Article
Closed access
PDF file
RLRomain Léguillon
Romain Léguillon
RVRémi Varin
Rémi Varin
TPThibaut Pressat-Laffouilhère
Thibaut Pressat-Laffouilhère
CCCatherine Chenailler
Catherine Chenailler
PCPhilippe Chassagne
Philippe Chassagne
FRFrédéric Roca
Frédéric Roca
Introduction: Clinical pharmacist (CP) intervention improves drug prescription by identifying potentially inappropriate prescriptions (PIPs). Geriatric perioperative care units (UPOGs) provide enhanced care for patients with hip fracture, including drug prescription. However, it is not known whether adding a CP intervention in a UPOG decreases the number of PIPs. This study aimed to evaluate the effect of a CP intervention, combining an implicit and an explicit method, on the number of PIPs in a UPOG. Methods: This single centre before-after-control-impact study recruited patients aged over 75 years admitted to a UPOG for a hip fracture. The “control group” (“before period”) received usual care including two medication reconciliations, one at admission and one at discharge. The “intervention group” (“after period”) received usual care and a CP intervention including two medication reconciliations, a medication review with two tools, STOPP/START and Medication Appropriateness Index, and a meeting between a CP and geriatricians. PIPs were assessed in both groups by STOPP/START and Medication Appropriateness Index and compared from hospital admission to discharge. Results: A total of 209 patients were included, 150 in the control group and 59 in the intervention group (mean age: 87.2 ± 5.9 years). The number of PIPs decreased in both groups from hospital admission to discharge (p < 0.001). The number of PIPs, potentially inappropriate medications, and potential prescribing omissions decreased more in the intervention group than in the control group (adjusted intervention effect: −2.46 (95% CI: −2.63; −2.24); −1.13 (95% CI: −1.27; −0.98); and −1.35 (95% CI: −1.52; −1.18), respectively, p < 0.001 for all). Discussion/Conclusion: A CP intervention with an explicit and implicit method improved prescriptions in a UPOG. Further randomized studies are necessary to evaluate the effect of a CP intervention on adverse drug events, health costs, and mortality.

EBEric BARAT
Eric BARAT
CCCatherine Chenailler
Catherine Chenailler
AGAndré Gillibert
André Gillibert
SPSophie Pouplin
Sophie Pouplin
RVRemi Varin
Remi Varin
VCVincent Compere
Vincent Compere
Post-operative pain is a common symptom of ambulatory surgery. The objective of this study was to evaluate a pain management protocol integrating a pharmacist consultation. We conducted a quasi-experimental, single center, before-after study. The control group was recruited between 1 March and 31 May 2018 and the intervention group between 1 March and 31 May 2019. Outpatients in the intervention group received a pharmacist consultation, in addition to the usual anesthesiologist and nurse consultations. Pharmacist consultations were conducted in two steps: the first step consisted of general open-ended questions and the second step of a specific and individualized pharmaceutical interview. A total of 125 outpatients were included in each group. There were 17% (95% CI 5 to 27%, p = 0.022) fewer patients with moderate to severe pain in the pharmaceutical intervention group compared with the control group, which corresponded to a decrease in the mean pain level of 0.9/10 (95% CI −1.5/10; −0.3/10; p = 0.002). The multivariate analysis did not reveal any confounding factors, showing that only the pharmaceutical intervention could explain this result. This study demonstrates a positive impact of pharmacist consultations on postoperative pain in ambulatory surgery.

23 July 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
EBEric BARAT
Eric BARAT
ASAnnaelle Soubieux
Annaelle Soubieux
PBPauline Brevet
Pauline Brevet
BGBaptiste Gerard
Baptiste Gerard
OVOlivier Vittecoq
Olivier Vittecoq
CLClaire Lattard
Claire Lattard
This is a systematic literature review on the impact of pharmacists in rheumatology, conducted using the PubMed®, CINAHL®, Cochrane Library®, and Web of science® databases and using the PRISMA 2020 checklist. This review was conducted from 2000 to June 2024. A quality analysis was performed. The selection of articles, as well as all analyses, including quality analyses, were conducted by a pair of pharmacists with experience in rheumatology, and included 24 articles. This study highlights the growth of clinical pharmacy activities in rheumatology and the positive influence of clinical pharmacists on patient care. The implementation of such initiatives has the potential to improve medication adherence, reduce medication-related risks, and optimize associated healthcare costs. All these pharmaceutical interventions aim to make the patient care journey smoother and safer. Additionally, the diversity of available pharmaceutical services caters to the varied needs of rheumatology. Furthermore, outpatient clinical pharmacy is also explored in this field and garners interest from patients. The vast majority of studies demonstrate significant improvement in patient care with promising performance outcomes when pharmacists are involved. This review highlights the diverse range of interventions by clinical pharmacists in rheumatology, which is very promising. However, to better assess the benefits of clinical pharmacists, this activity needs further development and evaluation through controlled and randomized clinical research programs.

1 May 2022 in Therapies
Verified
Journal Article
Closed access
HSHugo Mouton Sclaunich
Hugo Mouton Sclaunich
CMCharlotte Marchand
Charlotte Marchand
ARAmine Rekik
Amine Rekik
CCCatherine Chenailler
Catherine Chenailler
RVRémi Varin
Rémi Varin
JDJean Doucet
Jean Doucet

6 July 2023 in Soins Gérontologie
Verified
Journal Article
Closed access
ADAmaury Durand
Amaury Durand
BRBaptiste Routier
Baptiste Routier
LDLaurent Druesne
Laurent Druesne
MDManuella Dubois-Laurent
Manuella Dubois-Laurent
FRFrédéric ROCA
Frédéric ROCA
CCCatherine Chenailler
Catherine Chenailler

3 June 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
MZMIRIAM ZEINO
MIRIAM ZEINO
RLRomain Léguillon
Romain Léguillon
PBPauline Brevet
Pauline Brevet
BGBaptiste Gerard
Baptiste Gerard
CCCatherine Chenailler
Catherine Chenailler
EBEric BARAT
Eric BARAT
The evolving landscape of opioid prescription practices necessitates a comprehensive understanding of emerging patterns, particularly among new opioid users discharged from emergency departments. This study delves into the intricate realm of opioid utilization by elucidating the prevalence of their prescriptions. A retrospective analysis of electronic health records was conducted, including a cohort of 71 patients who received opioid prescriptions upon discharge from emergency departments from 1 January 2022 to 30 June 2022. Demographic characteristics and prescription details were systematically examined. This study illuminates tramadol’s prominence, with 84% of prescriptions and a Defined Daily Dose (DDD) morphine equivalent of 60 mg, as the primary choice as a new opioid, a finding that draws attention due to the closely aligned dosages with morphine equivalents. This discovery prompts a critical reassessment of tramadol’s therapeutic role, considering its multifaceted nature encompassing serotonergic effects and heightened fall risks. This study advocates for a nuanced and vigilant approach to tramadol prescription, cognizant of its potential risks and therapeutic implications, and highlights the imperative of optimizing data quality and traceability within electronic health records to enhance patient care and facilitate future research endeavors.